Cytomx Therapeutics Stock Gross Profit

CTMX Stock

USD 0.89 0.02 2.30%

CytomX Therapeutics fundamentals help investors to digest information that contributes to CytomX Therapeutics' financial success or failures. It also enables traders to predict the movement of CytomX Stock. The fundamental analysis module provides a way to measure CytomX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytomX Therapeutics stock.

	Last Reported	Projected for Next Year
Gross Profit	99 M	53.9 M
Gross Profit Margin	0.98	0.74

Gross Profit is likely to drop to about 53.9 M in 2024. Gross Profit Margin is likely to drop to 0.74 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

CytomX Therapeutics Company Gross Profit Analysis

CytomX Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current CytomX Therapeutics Gross Profit

53.16 M

Most of CytomX Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

CytomX Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Gross Profit. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.65	0.56	-0.84	-0.6	0.67	0.19	-0.11	0.9	0.89	1.0	0.55	-0.52	-0.11	0.44	0.84	0.82	-0.11	0.56	-0.02	-0.29	-0.11
Total Stockholder Equity	0.65		-0.12	-0.63	0.05	0.78	-0.33	0.28	0.61	0.24	0.66	0.69	0.1	0.28	0.21	0.9	0.18	0.28	0.0	0.57	0.34	0.28
Current Deferred Revenue	0.56	-0.12		-0.22	-0.98	0.08	0.49	-0.68	0.59	0.74	0.53	0.14	-0.94	-0.68	0.27	0.26	0.88	-0.68	0.88	-0.77	-0.94	-0.68
Net Debt	-0.84	-0.63	-0.22		0.32	-0.64	-0.28	-0.38	-0.63	-0.76	-0.84	-0.38	0.29	-0.38	-0.35	-0.73	-0.53	-0.38	-0.38	-0.22	-0.06	-0.38
Retained Earnings	-0.6	0.05	-0.98	0.32		-0.13	-0.5	0.57	-0.59	-0.76	-0.57	-0.11	0.97	0.57	-0.36	-0.33	-0.89	0.57	-0.94	0.73	0.93	0.57
Accounts Payable	0.67	0.78	0.08	-0.64	-0.13		0.05	0.12	0.63	0.39	0.69	0.79	0.02	0.12	0.3	0.86	0.24	0.12	0.03	0.21	0.14	0.12
Net Receivables	0.19	-0.33	0.49	-0.28	-0.5	0.05		-0.03	0.2	0.47	0.19	0.04	-0.45	-0.03	-0.05	0.0	0.33	-0.03	0.38	-0.69	-0.45	-0.03
Good Will	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03		-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74	1.0
Short Term Investments	0.9	0.61	0.59	-0.63	-0.59	0.63	0.2	-0.24		0.78	0.91	0.75	-0.52	-0.24	0.29	0.82	0.78	-0.24	0.54	-0.15	-0.35	-0.24
Total Liab	0.89	0.24	0.74	-0.76	-0.76	0.39	0.47	-0.18	0.78		0.87	0.29	-0.72	-0.18	0.44	0.53	0.92	-0.18	0.73	-0.33	-0.51	-0.18
Total Current Assets	1.0	0.66	0.53	-0.84	-0.57	0.69	0.19	-0.11	0.91	0.87		0.58	-0.49	-0.11	0.41	0.84	0.8	-0.11	0.53	0.0	-0.26	-0.11
Short Term Debt	0.55	0.69	0.14	-0.38	-0.11	0.79	0.04	-0.06	0.75	0.29	0.58		-0.01	-0.06	-0.06	0.78	0.23	-0.06	0.04	0.11	0.08	-0.06
Intangible Assets	-0.52	0.1	-0.94	0.29	0.97	0.02	-0.45	0.47	-0.52	-0.72	-0.49	-0.01		0.47	-0.32	-0.25	-0.85	0.47	-0.98	0.69	0.9	0.47
Common Stock	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47		-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74	1.0
Property Plant Equipment	0.44	0.21	0.27	-0.35	-0.36	0.3	-0.05	-0.07	0.29	0.44	0.41	-0.06	-0.32	-0.07		0.28	0.46	-0.07	0.35	-0.11	-0.28	-0.07
Net Tangible Assets	0.84	0.9	0.26	-0.73	-0.33	0.86	0.0	0.07	0.82	0.53	0.84	0.78	-0.25	0.07	0.28		0.47	0.07	0.32	0.19	-0.03	0.07
Deferred Long Term Liab	0.82	0.18	0.88	-0.53	-0.89	0.24	0.33	-0.47	0.78	0.92	0.8	0.23	-0.85	-0.47	0.46	0.47		-0.47	0.84	-0.45	-0.72	-0.47
Short Long Term Debt	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47		-0.37	0.6	0.74	1.0
Capital Surpluse	0.56	0.0	0.88	-0.38	-0.94	0.03	0.38	-0.37	0.54	0.73	0.53	0.04	-0.98	-0.37	0.35	0.32	0.84	-0.37		-0.58	-0.83	-0.37
Net Invested Capital	-0.02	0.57	-0.77	-0.22	0.73	0.21	-0.69	0.6	-0.15	-0.33	0.0	0.11	0.69	0.6	-0.11	0.19	-0.45	0.6	-0.58		0.88	0.6
Net Working Capital	-0.29	0.34	-0.94	-0.06	0.93	0.14	-0.45	0.74	-0.35	-0.51	-0.26	0.08	0.9	0.74	-0.28	-0.03	-0.72	0.74	-0.83	0.88		0.74
Capital Stock	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74

Click cells to compare fundamentals

CytomX Gross Profit Historical Pattern

Today, most investors in CytomX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CytomX Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CytomX Therapeutics gross profit as a starting point in their analysis.

CytomX Therapeutics Gross Profit

Timeline

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict CytomX Therapeutics

Gross Profit Over Time

According to the company disclosure, CytomX Therapeutics reported 53.16 M of gross profit. This is 97.63% lower than that of the Biotechnology sector and 94.41% lower than that of the Health Care industry. The gross profit for all United States stocks is 99.81% higher than that of the company.

CytomX Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.

CytomX Therapeutics is currently under evaluation in gross profit category among its peers.

CytomX Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	376.7M	302.3M	277.8M	105.2M	114.4M	108.7M
Enterprise Value	213.2M	135.3M	90.3M	(70.4M)	111.2M	105.6M

CytomX Fundamentals

	Return On Equity	-54.75
	Return On Asset	0.0233
	Profit Margin	0.11 %
	Operating Margin	0.12 %
	Current Valuation	(37.34 M)
	Shares Outstanding	78.26 M
	Shares Owned By Insiders	1.00 %
	Shares Owned By Institutions	65.31 %
	Number Of Shares Shorted	5.67 M
	Price To Earning	(11.41) X
	Price To Book	5.04 X
	Price To Sales	0.55 X
	Revenue	101.21 M
	Gross Profit	53.16 M
	EBITDA	(4.31 M)
	Net Income	(569 K)
	Cash And Equivalents	194.29 M
	Cash Per Share	2.94 X
	Total Debt	13.97 M
	Debt To Equity	0.67 %
	Current Ratio	2.05 X
	Book Value Per Share	(0.30) X
	Cash Flow From Operations	(56.03 M)
	Short Ratio	9.58 X
	Earnings Per Share	0.16 X
	Price To Earnings To Growth	(1.80) X
	Target Price	5.29
	Number Of Employees	120
	Beta	1.06
	Market Capitalization	69.65 M
	Total Asset	201.79 M
	Retained Earnings	(723.45 M)
	Working Capital	27.02 M
	Current Asset	189.75 M
	Current Liabilities	15.74 M
	Net Asset	201.79 M

About CytomX Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC